Study 329's Troubling Findings and Controversies

Study 329 was a clinical trial conducted by GlaxoSmithKline that tested the antidepressant drug Paxil on adolescents. The trial was funded by the company and was designed to determine the efficacy of Paxil in treating depression in teenagers.

The trial was plagued by controversy from the start, with concerns raised about the safety of the drug for young people. The trial's findings were also called into question due to methodological flaws and inconsistencies in the data.

According to the trial's results, Paxil was shown to be effective in treating depression in adolescents, but the study's authors failed to disclose the high rates of suicidal thoughts and behaviors reported by the participants. This omission was seen as a major red flag by critics of the study.

The trial's findings were also criticized for being based on a small sample size and a flawed statistical analysis. The study's authors were accused of cherry-picking data to support their conclusions and ignoring contradictory evidence.

Discover more: Meyer Brothers Drug Company

The conclusions drawn from Study 329 were questionable, with the authors noting that the differences between paroxetine and placebo were small.

Neither paroxetine nor imipramine differed significantly from placebo for parent-or self-rating measures of depression.

Serious adverse events occurred in 11 patients in the paroxetine group, 5 in the imipramine group, and 2 in the placebo group.

Ten of the 11 serious adverse events in the paroxetine group were psychiatric, including depression, suicidality, hostility, or euphoria.

Garland pointed out the "weak or nonexistent evidence of efficacy" of SSRIs in this setting and the "serious psychiatric adverse effects" of paroxetine in 2004.

Curious to learn more? Check out: General Motors Chapter 11 Reorganization

The RIAT initiative is an attempt by independent researchers to analyze and publish misreported or unpublished trials.

The researchers identified Study 329 as an example of a potentially misreported acute phase trial in need of restoration and an unpublished continuation phase trial that had been abandoned.

They followed the protocol established by GSK and used all appropriate procedural steps to avoid bias in their re-analysis.

Take a look at this: Docusign Free Trial Limitations

The researchers made the original anonymous patient data available for others to analyze.

The restored trial and the abandoned trial are now published, providing a detailed report of the methods used to re-analyze Study 329.

The publications report in detail the methods used to re-analyze Study 329, following the protocol established by GSK.

For more insights, see: Quasi-Monte Carlo Methods in Finance

The RIAT analysis of Study 329 is a crucial part of understanding the trial's results. The trial protocol specified two primary efficacy variables: change in total score on a Hamilton depression rating scale (HAM-D) from baseline to endpoint, and the proportion of responders at the end of 8 weeks.

Responders were defined as achieving a reduction of ≥ 50% in HAM-D score, or a score of ≤ 8. Paroxetine and imipramine were not statistically or clinically significantly different from placebo for any of the 9 pre-specified primary or secondary efficacy outcomes.

Withdrawals due to adverse effects occurred in 15% of subjects taking paroxetine, 32.6% taking imipramine and 6.9% taking placebo. More paroxetine adverse events were rated as severe, and the most common adverse psychiatric effects occurred in 12% of subjects taking paroxetine.

Take a look at this: Economic Effects of the September 11 Attacks

The RIAT analysis of Study 329's acute phase reveals some disturbing findings.

The trial protocol specified two primary efficacy variables: change in total score on a Hamilton depression rating scale (HAM-D) from baseline to endpoint, and the proportion of responders at the end of 8 weeks.

Responders were defined as achieving a reduction of ≥ 50% in HAM-D score, or a score of ≤ 8. It also specified seven secondary efficacy variables.

Paroxetine and imipramine were not statistically or clinically significantly different from placebo for any of the 9 pre-specified primary or secondary efficacy outcomes.

The four statistically significant outcomes in the 2001 publication were neither specified in the original protocol nor in any amendment.

Withdrawals due to adverse effects occurred in 15% of subjects taking paroxetine, 32.6% taking imipramine and 6.9% taking placebo.

More paroxetine adverse events were rated as severe.

This RIAT analysis highlights the importance of independent access to data and the value of reanalysis of trials.

See what others are reading: Executive Coaching Outcomes

The RIAT analysis of the continuation phase of Study 329 showed that 119 adolescents entered this phase after completing the acute phase. Of these, 49 were on paroxetine, 39 on imipramine, and 31 on placebo.

The response rate at 6 months was the same for all three treatments: 31% on paroxetine, 31% on imipramine, and 39% on placebo. This suggests that the continuation phase did not offer support for longer-term efficacy of either paroxetine or imipramine.

Adverse event rates were similar for the three groups during the continuation phase. However, during the tapering phase, severe adverse events were much higher for the drugs: 16 events on paroxetine, 14 events on imipramine, and only 1 event on placebo.

Suicidality and suicide-related events were a particular concern during the taper phase, with 5 of the 23 events on paroxetine occurring in 5 patients during this phase.

Discover more: September 2019 Events in the U.S. Repo Market

The researchers behind Study 329 were Jon Jureidini, a Research Leader at the Critical and Ethical Mental Health research group, and Melissa Raven, a Postdoctoral research fellow at the University of Adelaide.

Jon Jureidini was the lead researcher at the time, and Melissa Raven was a postdoctoral research fellow, which suggests she was in a junior role to Jureidini.

A different take: Jon Moulton

The authors behind Study 329 are Jon Jureidini and Melissa Raven.

Jon Jureidini is the Research Leader of the Critical and Ethical Mental Health research group at the Robinson Research Institute, University of Adelaide.

Melissa Raven is a Postdoctoral research fellow at the University of Adelaide.

For your interest: Jon Moynihan, Baron Moynihan of Chelsea

The clinical study report for paroxetine had significant problems, including omitting many adverse events found in the case report forms for individual patients.

Researchers in this clinical trial used ten strategies to minimize apparent harms, including inconsistent classification of adverse events and ignoring their severity.

These strategies can be readily identified in reports of other trials, influencing the apparent safety of drugs and presenting them in a favourable or unfavourable light.

Selective reporting is common in psychiatric literature, and our findings show that influential peer-reviewed research can be seriously misleading.

The clinical study report for paroxetine omitted many problems, including more than twice as many severe adverse events and four times as many psychiatric adverse events compared to the placebo group.

Suggestion: Forex Trading Scalping Strategies

We can't adequately scrutinize trial outcomes, particularly in relation to harms, just by reading what's written in the body of clinical study reports, which can contain important errors.

The imipramine group had significantly more heart problems compared to the placebo group.

Our re-analysis of the evidence has implications beyond Study 329, affecting all of evidence-based medicine.

For your interest: Corporate Valuation Theory Evidence and Practice

The Study 329 controversy is a prime example of how the line between marketing and science can be blurred. Drug makers can try to expand the uses for their medications and the populations taking them, often with lax regulatory oversight.

In the case of Study 329, the publication in 2001 provided a major boost to the marketing of Paxil, with sales reaching $2.68 billion US worldwide that year.

The study's conclusion that Paxil is safe and effective for children and adolescents was based on data that is incompatible with the actual results, which showed an ineffective medication with many serious side effects, some deadly.

Despite the serious harms caused by Paxil/Seroxat, all parties involved with the publication of Study 329 have refused to request retraction.

Letter 101 shows that the conclusions about a study can be misleading. The study found that paroxetine wasn't significantly better than a placebo for imipramine in treating adolescents with major depression.

The study was very influential, with over 600 citations. This suggests that the study's findings were widely accepted by the medical community.

The study's published conclusions were based on the authors' analysis, but the authors' conclusions were later disputed by an independent analysis. This highlights the importance of independent analysis in evaluating the results of a study.

The independent analysis of Study 329 found serious harms and a lack of efficacy for acute and longer-term use of paroxetine and imipramine in adolescents with major depression. This raises questions about the safety and effectiveness of these medications.

Good science demands access to the data. The publication of Study 329 in 2001 provides a major boost to the cause of transparency in clinical trials.

The study's conclusion, that Paxil is safe and effective for children and adolescents, was used to promote the use of the drug despite data showing it to be ineffective and having many serious side effects.

In 2000-01, GSK was the second-fastest-growing drug company, and Paxil was its #1 seller, generating $2.68 billion in US worldwide sales.

The data from Study 329 show that Paxil is not effective for acute and longer-term use in adolescents with major depression. This is in contrast to the study's published conclusion that paroxetine is generally well-tolerated and effective.

The study's authors' conclusion was based on a flawed analysis that ignored the data. This is a major concern in the scientific community, where data-driven conclusions are essential.

The lack of transparency in clinical trials has serious consequences. In the case of Study 329, the failure to disclose the data led to the deaths and harm of many people.

Independent analysis of Study 329 demonstrated serious harms and a lack of efficacy for acute and longer-term use of paroxetine and imipramine for adolescents with major depression.

The study has been cited over 600 times, and its conclusions have influenced prescribing practices in the clinical setting.

For your interest: We No Longer except Personal Checks

The documents related to Study 329 are extensive and reveal a complex history of the study's development and publication.

The Final Clinical Report was first drafted on December 18, 1998, and underwent several revisions before being submitted to JAMA on July 30, 1999.

A teleconference on April 22, 1997, discussed the efficacy analysis of Paroxetine Study 329.

The study's protocol was amended on March 24, 1994, and a position piece on the phase III clinical studies was written on October 14, 1998.

The study's documents include drafts of the Final Clinical Report, peer reviews, and responses to reviewers.

Here are the key documents related to Study 329:

These documents provide a detailed look at the development and publication of Study 329, and highlight the complex interactions between the researchers, reviewers, and pharmaceutical company.

The study was conducted by GlaxoSmithKline (GSK) to evaluate the efficacy and safety of paroxetine, an antidepressant, in treating depression in adolescents.

The study was stopped prematurely due to a lack of efficacy.

A total of 275 adolescents were enrolled in the study, with 196 receiving paroxetine and 79 receiving a placebo.

The study found that paroxetine was no more effective than the placebo in treating depression in adolescents.

The study also found that adolescents taking paroxetine were more likely to experience suicidal thoughts and behaviors compared to those taking the placebo.

The study's results were not made public until 2006, when the data was released due to a Freedom of Information Act request.

The study's findings have been widely criticized for their potential impact on the treatment of depression in adolescents.

See what others are reading: Risk of Receiving Wire Transfer